SCHEMBL18285607

SCHEMBL18285607

COc1ccc(CN(Cc2ccc(OC)cc2)c2nccc3c2n(-c2ccc(Oc4ccccc4)cc2)c(=O)n3CC2CCCN2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 17/20 0.54
▸ TP53 P04637 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ TEC P42680 1/20 0.38
▸ CD69 Q07108 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18285610 1.00 BTK (0.54) BTKTP53EGFRTECCD69
SCHEMBL28484529 0.92 BTK (0.54) BTKEGFRTECCD69HRH3
SCHEMBL18285534 0.89 BTK (0.49) BTKEGFRTECCD69HRH3
SCHEMBL23450721 0.84 BTK (0.57) BTKEGFRTECCD69
SCHEMBL30111802 0.84 BTK (0.57) BTKEGFRTECCD69
SCHEMBL18290007 0.84 BTK (0.57) BTKEGFRTECCD69
SCHEMBL18818206 0.82 HRH3 (0.39) BTKTP53HRH3
SCHEMBL18818205 0.82 HRH3 (0.39) BTKTP53HRH3
SCHEMBL18818235 0.78 BTK (0.58) BTKEGFRTECCD69
SCHEMBL18818236 0.78 BTK (0.58) BTKEGFRTECCD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 — — US disclosed
US-20230151012-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2023-05-18 — — US disclosed
EP-4112618-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2023-01-04 — — EP disclosed
EP-3912979-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2021-11-24 — — EP disclosed
US-20210171526-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-06-10 — — US disclosed
EP-3303334-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2021-06-02 — — EP disclosed
US-20180162861-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2018-06-14 — — US disclosed
EP-3303334-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2018-04-11 — — EP disclosed
US-9688676-B2 Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC. (US) 2017-06-27 — — US disclosed
US-20170129890-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2017-05-11 — — US disclosed
WO-2016196840-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2016-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171526-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK BTK 1/4885TP53 606/4885EGFR 237/4885
US-20180162861-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK BTK 1/4885TP53 606/4885EGFR 237/4885
US-20170129890-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK BTK 1/4885TP53 606/4885EGFR 237/4885
US-20230151012-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK BTK 1/4885TP53 606/4885EGFR 237/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK BTK 1/4885TP53 606/4885EGFR 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback